Demographics, baseline disease characteristics, and previous therapies for the overall population and group I patients who received RO7283420 IV
| . | Overall population (N = 62) . | Group I, IV administration (n = 51) . |
|---|---|---|
| Age, median (range), y | 65.5 (35-84) | 66 (35-84) |
| ≥65 years, n (%) | 36 (58.1) | 30 (58.8) |
| Male sex, n (%) | 34 (54.8) | 30 (58.8) |
| Race, n (%) | ||
| Asian | 10 (16.1) | 8 (15.7) |
| White | 50 (80.6) | 41 (80.4) |
| Unknown | 2 (3.2) | 2 (3.9) |
| ECOG PS, n (%) | ||
| 0 | 36 (58.1) | 29 (56.9) |
| 1 | 23 (37.1) | 19 (37.3) |
| 2 | 3 (4.8) | 3 (5.9) |
| Primary refractory, n (%) | 23 (37.1) | 21 (41.2) |
| Relapsed, n (%) | 34 (54.8) | 30 (58.8) |
| ELN risk category, n (%) | ||
| Favorable | 6 (9.7) | 5 (9.8) |
| Intermediate | 22 (35.5) | 19 (37.3) |
| Adverse | 32 (51.6) | 25 (49) |
| Missing | 2 (3.2) | 2 (3.9) |
| BM blast count category, n (%) | ||
| <30% | 28 (45.2) | 20 (39.2) |
| ≥30 to <50% | 13 (21) | 13 (25.5) |
| ≥50% | 19 (30.6) | 17 (33.3) |
| Missing | 2 (3.2) | 1 (2) |
| Number of previous AML therapies | ||
| Median (range) | 2 (1-5) | 2 (1-5) |
| 1, n (%) | 14 (22.6) | 7 (13.7) |
| 2, n (%) | 28 (45.2) | 25 (49) |
| >2, n (%) | 20 (32.3) | 19 (37.3) |
| Previous HSCT, n (%) | 18 (29) | 15 (29.4) |
| Previous AML therapy, induction/re-induction, n (%)∗ | 58 (93.5) | 48 (94.1) |
| Cytarabine | 48 (77.4) | 39 (76.5) |
| Idarubicin | 29 (46.8) | 24 (47.1) |
| Fludarabine | 22 (35.5) | 18 (35.3) |
| Azacitidine | 18 (29.0) | 15 (29.4) |
| Daunorubicin | 17 (27.4) | 15 (29.4) |
| Venetoclax | 16 (25.8) | 15 (29.4) |
| Gemtuzumab | 6 (9.7) | 6 (11.8) |
| Previous AML therapy, consolidation/conditioning/maintenance/other, n (%)∗ | 40 (64.5) | 34 (66.7) |
| Cytarabine | 25 (40.3) | 21 (41.2) |
| Azacitidine | 22 (35.5) | 18 (35.3) |
| Venetoclax | 13 (21.0) | 12 (23.5) |
| Fludarabine | 10 (16.1) | 8 (15.7) |
| . | Overall population (N = 62) . | Group I, IV administration (n = 51) . |
|---|---|---|
| Age, median (range), y | 65.5 (35-84) | 66 (35-84) |
| ≥65 years, n (%) | 36 (58.1) | 30 (58.8) |
| Male sex, n (%) | 34 (54.8) | 30 (58.8) |
| Race, n (%) | ||
| Asian | 10 (16.1) | 8 (15.7) |
| White | 50 (80.6) | 41 (80.4) |
| Unknown | 2 (3.2) | 2 (3.9) |
| ECOG PS, n (%) | ||
| 0 | 36 (58.1) | 29 (56.9) |
| 1 | 23 (37.1) | 19 (37.3) |
| 2 | 3 (4.8) | 3 (5.9) |
| Primary refractory, n (%) | 23 (37.1) | 21 (41.2) |
| Relapsed, n (%) | 34 (54.8) | 30 (58.8) |
| ELN risk category, n (%) | ||
| Favorable | 6 (9.7) | 5 (9.8) |
| Intermediate | 22 (35.5) | 19 (37.3) |
| Adverse | 32 (51.6) | 25 (49) |
| Missing | 2 (3.2) | 2 (3.9) |
| BM blast count category, n (%) | ||
| <30% | 28 (45.2) | 20 (39.2) |
| ≥30 to <50% | 13 (21) | 13 (25.5) |
| ≥50% | 19 (30.6) | 17 (33.3) |
| Missing | 2 (3.2) | 1 (2) |
| Number of previous AML therapies | ||
| Median (range) | 2 (1-5) | 2 (1-5) |
| 1, n (%) | 14 (22.6) | 7 (13.7) |
| 2, n (%) | 28 (45.2) | 25 (49) |
| >2, n (%) | 20 (32.3) | 19 (37.3) |
| Previous HSCT, n (%) | 18 (29) | 15 (29.4) |
| Previous AML therapy, induction/re-induction, n (%)∗ | 58 (93.5) | 48 (94.1) |
| Cytarabine | 48 (77.4) | 39 (76.5) |
| Idarubicin | 29 (46.8) | 24 (47.1) |
| Fludarabine | 22 (35.5) | 18 (35.3) |
| Azacitidine | 18 (29.0) | 15 (29.4) |
| Daunorubicin | 17 (27.4) | 15 (29.4) |
| Venetoclax | 16 (25.8) | 15 (29.4) |
| Gemtuzumab | 6 (9.7) | 6 (11.8) |
| Previous AML therapy, consolidation/conditioning/maintenance/other, n (%)∗ | 40 (64.5) | 34 (66.7) |
| Cytarabine | 25 (40.3) | 21 (41.2) |
| Azacitidine | 22 (35.5) | 18 (35.3) |
| Venetoclax | 13 (21.0) | 12 (23.5) |
| Fludarabine | 10 (16.1) | 8 (15.7) |
AML, acute myeloid leukemia; BM, bone marrow; ECOG, Eastern Cooperative Oncology Group; ELN, European LeukemiaNet; HSCT, hematopoietic stem cell transplantation; IV, intravenous; PS, performance status.
Data are displayed for the therapies that were received by ≥10% of patients in group I who received IV RO7283420.